These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

791 related items for PubMed ID: 29938884

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R, Bossart M, Herling AW, Weiss T, Zhang B, Kannt A, Wagner M, Haack T, Evers A, Dudda A, Keil S, Lorenz M, Lorenz K, Riz M, Hennerici W, Larsen PJ.
    Endocrinology; 2018 Aug 01; 159(8):3105-3119. PubMed ID: 29992313
    [Abstract] [Full Text] [Related]

  • 3. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Löfmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP.
    Diabetes Obes Metab; 2016 Dec 01; 18(12):1176-1190. PubMed ID: 27377054
    [Abstract] [Full Text] [Related]

  • 4. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK, Deryabina MA, Tofteng Shelton P, Fog JU, Daugaard JR, Eriksson PO, Larsen LF, Jessen L.
    Diabetes Obes Metab; 2018 Jan 01; 20(1):60-68. PubMed ID: 28598027
    [Abstract] [Full Text] [Related]

  • 5. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L, Martel E, Rist W, Uphues I, Hamprecht D, Neubauer H, Augustin R.
    Diabetes Obes Metab; 2024 Jun 01; 26(6):2368-2378. PubMed ID: 38560764
    [Abstract] [Full Text] [Related]

  • 6. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C, Sun Y, Yang Q, Zhou F, Chen X, Wu L, Sun L, Han J.
    Mol Pharm; 2021 Aug 02; 18(8):2906-2923. PubMed ID: 34240881
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner.
    Blevins JE, Honeycutt MK, Slattery JD, Goldberg M, Rambousek JR, Tsui E, Dodson AD, Shelton KA, Salemeh TS, Elfers CT, Chichura KS, Ashlaw EF, Zraika S, Doyle RP, Roth CL.
    Front Endocrinol (Lausanne); 2024 Aug 02; 15():1432928. PubMed ID: 39104812
    [Abstract] [Full Text] [Related]

  • 9. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA, Finan B, Gelfanov V, Yang B, Tschöp MH, DiMarchi RD, Perez-Tilve D.
    Mol Metab; 2019 Feb 02; 20():51-62. PubMed ID: 30578168
    [Abstract] [Full Text] [Related]

  • 10. Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons.
    Adams JM, Pei H, Sandoval DA, Seeley RJ, Chang RB, Liberles SD, Olson DP.
    Diabetes; 2018 Aug 02; 67(8):1538-1548. PubMed ID: 29776968
    [Abstract] [Full Text] [Related]

  • 11. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V, Hogg C, Flatt PR, O'Harte FPM.
    Diabetes Obes Metab; 2018 Feb 02; 20(2):319-327. PubMed ID: 28730728
    [Abstract] [Full Text] [Related]

  • 12. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
    Jiang P, Zeng Y, Yang W, Li L, Zhou L, Xiao L, Li Y, Gu B, Li X, Li J, Li W, Guo L.
    Biomed Pharmacother; 2024 May 02; 174():116485. PubMed ID: 38518602
    [Abstract] [Full Text] [Related]

  • 13. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
    Wang W, Wen X, Duan W, Wang X, Chen Y, Dong J, Yang Z, Fang J, Zhou Z, Yao G, Fang Y, Huang Y.
    J Endocrinol Invest; 2020 May 02; 43(5):653-662. PubMed ID: 31786794
    [Abstract] [Full Text] [Related]

  • 14. A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes.
    Zhao S, Yan Z, Du Y, Li Z, Tang C, Jing L, Sun L, Yang Q, Tang X, Yuan Y, Han J, Jiang N.
    Br J Pharmacol; 2022 Sep 02; 179(17):4360-4377. PubMed ID: 35484823
    [Abstract] [Full Text] [Related]

  • 15. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
    Clemmensen C, Finan B, Fischer K, Tom RZ, Legutko B, Sehrer L, Heine D, Grassl N, Meyer CW, Henderson B, Hofmann SM, Tschöp MH, Van der Ploeg LH, Müller TD.
    EMBO Mol Med; 2015 Mar 02; 7(3):288-98. PubMed ID: 25652173
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T, Norlin J, Bugge A, Gaalsgaard ED, Prada-Medina CA, Latta M, Veidal SS, Petersen PS, Feigh M, Holst D.
    Mol Metab; 2024 Jan 02; 79():101850. PubMed ID: 38065435
    [Abstract] [Full Text] [Related]

  • 17. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z, Zhou D, Yan J, Wang S, Yang X, Pei Z.
    Life Sci; 2020 Jul 15; 253():117651. PubMed ID: 32304764
    [Abstract] [Full Text] [Related]

  • 18. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist.
    Yuan Y, Yan Z, Lao Q, Jiang N, Wu S, Lu Q, Han J, Zhao S.
    Eur J Med Chem; 2023 Feb 05; 247():115036. PubMed ID: 36571995
    [Abstract] [Full Text] [Related]

  • 19. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS, Shankar RR, Mixson LA, Miller DL, Pramanik B, O'Dowd AK, Williams DM, Frederick CB, Beals CR, Stoch SA, Steinberg HO, Kelley DE.
    Diabetes; 2018 Jun 05; 67(6):1105-1112. PubMed ID: 29545266
    [Abstract] [Full Text] [Related]

  • 20. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
    Pickford P, Lucey M, Rujan RM, McGlone ER, Bitsi S, Ashford FB, Corrêa IR, Hodson DJ, Tomas A, Deganutti G, Reynolds CA, Owen BM, Tan TM, Minnion J, Jones B, Bloom SR.
    Mol Metab; 2021 Sep 05; 51():101242. PubMed ID: 33933675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.